Pembrolizumab (Keytruda) has received green light from the European Commission for the first-line treatment of a select population of adult patients with metastatic non-small cell lung cancer.
Merck has announced that its programmed death-1 (PD-1) inhibitor, pembrolizumab (Keytruda), has been given the green light by the European Commission for the first-line treatment of a select population of adult patients with metastatic non-small cell lung cancer (NSCLC).
Patients with tumors that harbor a high expression of the programmed death ligand-1 receptor, without mutations in EGFR or ALK, will qualify to receive pembrolizumab instead of standard-of-care chemotherapy.
The approval follows a review of phase 3 data from the KEYNOTE-024 trial, which showed that 80% of patients on pembrolizumab were alive 6 months following treatment initiation, compared with 72% on chemotherapy. Patients on pembrolizumab also had a higher overall response rate and duration of response compared with chemotherapy. The median progression-free survival with the PD-1 inhibitor was 10.3, compared with 6 months for patients receiving chemotherapy.
“The approval of Keytruda as a first treatment instead of chemotherapy for patients who express high levels of PD-L1 has the potential to transform the way metastatic non-small cell lung cancer is treated,” Roy Banes, MD, senior vice president, head of clinical development, and chief medical officer, Merck Research Laboratories, said in a statement. “We are committed to ensuring that patients in Europe—who are in need of new treatment options—are able to quickly gain access to Keytruda.”
Pembrolizumab was approved in the United States for the same indication in October 2016.
Nivolumab, a PD-1 inhibitor developed by Bristol-Myers Squibb, and a major competitor for pembrolizumab, lagged behind in the NSCLC race following disappointing phase 3 results.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More